Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.